All In Biotech

Free tool

FAERS Monitor: Astepro Allergy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213872 or its brand name (Astepro Allergy, Azelastine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,427

Serious

646

45% of reports

Hospitalization

278

Death reported

76

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective104
  • fatigue100
  • headache81
  • nausea74
  • diarrhoea73
  • dizziness60
  • dyspnoea54
  • pneumonia52
  • cough50
  • pain50
  • vomiting49
  • malaise47
  • somnolence47
  • asthenia46
  • pruritus41

Reports by year received

View as table
YearReports
200413
20056
20068
200715
200825
200922
201072
201146
201240
20136
201417
201562
2016112
2017111
2018140
2019162
2020182
2021133
20225
202334
20245
2025195
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,732 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
somnolenceSignal473.42.680
coughSignal502.62.049
pneumoniaSignal522.41.840
headache811.91.535
fatigue1001.91.643
asthenia461.81.416
dizziness601.81.420
diarrhoea731.71.319
malaise471.61.210
pruritus411.61.28
vomiting491.51.29
dyspnoea541.41.16
nausea741.41.18
pain501.20.92
drug ineffective1041.21.02

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.